Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

European Partners to Seek New Approaches for Dealing with Colorectal Cancer

By BiotechDaily International staff writers
Posted on 26 Dec 2013
A European research project is directed at finding new diagnostic and therapeutic tools to better find and treat patients with colorectal cancer.

Colorectal cancer (CRC) is the third most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the second most common cause of cancer death. More than half of all CRC patients develop distant metastases and have five-year overall survival of less than 5% because of ineffective treatments.

A six million euro research project on CRC funded by the European Commission's Framework VII Program called MErCuRIC is linked to a thousand-patient multicenter phase Ib/II clinical trial. Experiments have been designed to assess a novel therapeutic strategy that combines treatment with the MEK inhibitor PD-0325901 (MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells) and the MET (an oncogene that encodes hepatocyte growth factor receptor) inhibitor PF-02341066. It is expected that the combined treatment will combat metastasis, improve survival, and change current clinical practice for CRC patients with KRAS mutant (MT) and KRAS wild type (WT) (with aberrant c-MET) tumors.

The MErCuRIC research project, which comprises 13 partners in eight different European countries, will go beyond the current state-of-the- art by (i) employing a novel treatment strategy targeting the biology of the disease and by (ii) using next generation sequencing (NGS) to identify CRC patient subgroups who will maximally benefit from this novel treatment strategy.

Dr. Sandra van Schaeybroeck, professor of medicine at Queen's University (Belfast, United Kingdom), said, "Our research has identified two key genes that are contributing to the aggressive spread of colorectal cancer. The research being carried out by MErCuRIC will allow us to bring this research to the next level by developing and conducting a clinical trial that targets the products of these two genes in patients with metastic or aggressive colorectal cancer."

Dr. Tim Maughan, professor of clinical oncology at the University of Oxford (United Kingdom), said, "This is an important study, which has the potential to develop new approaches to treat patients who have what is essentially an incurable disease. Bringing together world leading researchers from across Europe has the potential to make important developments in the war against this very aggressive form of cancer."

Related Links:

MErCuRIC
Queen's University
University of Oxford



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

White-Matter Deficits Found in Codeine-Containing Cough Syrup Users

A magnetic resonance imaging (MRI) study of chronic users of codeine-containing cough syrups (CCS) has found deficits in specific regions of brain white matter and linked these changes with increased impulsivity in codeine-containing cough syrup users. These findings were consistent with findings from earlier research of... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.